SB-3CT
Modify Date: 2024-01-02 11:07:15
SB-3CT structure
|
Common Name | SB-3CT | ||
|---|---|---|---|---|
| CAS Number | 292605-14-2 | Molecular Weight | 306.400 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 501.4±46.0 °C at 760 mmHg | |
| Molecular Formula | C15H14O3S2 | Melting Point | 101 °C | |
| MSDS | Chinese USA | Flash Point | 257.1±29.0 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of SB-3CTSB-3CT is a potent and competitive inhibitor of matrix metalloproteinase (MMP-2) and MMP-9. |
| Name | 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane |
|---|---|
| Synonym | More Synonyms |
| Description | SB-3CT is a potent and competitive inhibitor of matrix metalloproteinase (MMP-2) and MMP-9. |
|---|---|
| Related Catalog | |
| Target |
MMP-2, MMP-9[1] |
| In Vitro | SB-3CT has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB-3CT inhibits MMP-9 with an inhibition constant Ki of 400±15 nM[1]. Inhibition of PC3 tumor growth by SB-3CT could also be a direct consequence of reduced extracellular matrix degradation within the bone tissue by the tumor cells themselves and/or by osteoclasts. Indeed, SB-3CT treatment is associated with a reduced osteolytic response, indicating that SB-3CT helps to preserve bone integrity[2]. |
| In Vivo | Post-ischemic treatment with SB-3CT significantly diminishes brain damage and reduced infarct volume to about 20% of the total hemisphere. SB-3CT treatment ameliorates neurobehavioral outcomes, particularly in the motor and sensory functions[3]. |
| Cell Assay | PC3 cells are seeded in 35-mm dishes (5×104 cells/dish) in complete culture medium. The next day, the medium is replaced with complete medium supplemented with 1% DMSO alone (vehicle) or SB-3CT (final concentrations 0.1-50 μM) in 1%DMSO. At various times, the cells are harvested with trypsin and counted[2]. |
| Animal Admin | Adult male C57Bl/6 J mice, 6-9 weeks of age and weighing 20-28 g are divided into four groups: vehicle-treated group and SB-3CT-treated one with treatment for either one day or seven days after embolic MCA occlusion. SB-3CT (12.5 mg/mL) is freshly dissolved in 25% DMSO/65% PEG-200/10% water and filtered through an Acrodisc syringe filter with a 0.2 μm, 13-mm diameter sterile hydrophobic PTFE membrane. Mice are ip injected with 2 μL/gram body weight of this solution (equivalent to 25 mg/kg) 2 hours after embolic ischemia, followed by an additional dose at 4 hours. In repeated-dose treatment conditions, the same dose of SB-3CT is ip administered 2 and 4 hours after embolic ischemia, followed by once daily from post-ischemia day 1 to 6. Earlier work indicated that ip administration of SB-3CT does not alter mean arterial blood pressure, pH, PCO2, and PO2. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 501.4±46.0 °C at 760 mmHg |
| Melting Point | 101 °C |
| Molecular Formula | C15H14O3S2 |
| Molecular Weight | 306.400 |
| Flash Point | 257.1±29.0 °C |
| Exact Mass | 306.038422 |
| PSA | 77.05000 |
| LogP | 3.36 |
| Appearance of Characters | white to off-white |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.628 |
| Storage condition | ?20°C |
| Water Solubility | DMSO: >20mg/mL |
|
Engineering the ovarian cycle using in vitro follicle culture.
Hum. Reprod. 30 , 1386-95, (2015) Can cultured follicles model the ovarian cycle, including follicular- and luteal-phase hormone synthesis patterns and ovulation?Under gonadotrophin stimulation, murine follicles grown in an encapsulat... |
|
|
Primitive macrophages control HSPC mobilization and definitive haematopoiesis.
Nat. Commun. 6 , 6227, (2015) In vertebrates, haematopoietic stem/progenitor cells (HSPCs) first emerge in the aorta-gonad-mesonephros (AGM) before colonizing transitory and subsequently definitive haematopoietic organs allowing h... |
|
|
Chemokine receptor 7 enhances cell chemotaxis and migration of metastatic squamous cell carcinoma of head and neck through activation of matrix metalloproteinase-9.
Oncol. Rep. 32(2) , 794-800, (2014) The mechanisms leading to squamous cell carcinoma of head and neck (SCCHN) metastasis are not fully understood. Although evidence shows that the chemokine receptor 7 (CCR7) and its ligand CCL19 may re... |
| 2-[[(4-phenoxyphenyl)sulfonyl]methyl]-Thiirane |
| 2-((4-phenoxyphenylsulfonyl)methyl)thiirane |
| IN1250 |
| 2-{[(4-Phenoxyphenyl)sulfonyl]methyl}thiirane |
| Thiirane, 2-[[(4-phenoxyphenyl)sulfonyl]methyl]- |
| MMP-2/MMP-9 Inhibitor IV |
| SB-3CT |